Cidara Therapeutics to Host Research and Development Day
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Patrick Bursey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
In February, the FDA declined to approve the company's new drug application as it was presented and asked the company to submit additional evidence of effectiveness for epidermolysis bullosa (EB).
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics...
For Trade and Medical Media Only Rezafungin is a next-generation once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis